GCH1 Haplotype Determines Vascular and Plasma Biopterin Availability in Coronary Artery Disease
|
|
- Shanon Long
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 52, No. 2, by the American College of Cardiology Foundation ISSN /8/$34. Published by Elsevier Inc. doi:1.116/j.jacc GCH1 Haplotype Determines Vascular and Plasma Biopterin Availability in Coronary Artery Disease Effects on Vascular Superoxide Production and Endothelial Function Vascular Disease Charalambos Antoniades, MD, PHD,* Cheerag Shirodaria, MRCP,* Tim Van Assche, PHD,* Colin Cunnington, MRCP,* Irmgard Tegeder, MD, PHD, Jörn Lötsch, MD, PHD, Tomasz J. Guzik, MD, PHD,* Paul Leeson, MRCP, PHD,* Jonathan Diesch, HNC,* Dimitris Tousoulis, MD, PHD, FACC, Christodoulos Stefanadis, MD, FACC, FESC, Michael Costigan, PHD, Clifford J. Woolf, MD, PHD, Nicholas J. Alp, MD, PHD, MRCP,* Keith M. Channon, MD, FRCP* Oxford, United Kingdom; Boston, Massachusetts; Frankfurt am Main, Germany; Cracow, Poland; and Athens, Greece Objectives Background Methods Results Conclusions This study sought to determine the effects of endogenous tetrahydrobiopterin (BH4) bioavailability on endothelial nitric oxide synthase (enos) coupling, nitric oxide (NO) bioavailability, and vascular superoxide production in patients with coronary artery disease (CAD). GTP-cyclohydrolase I, encoded by the GCH1 gene, is the rate-limiting enzyme in the biosynthesis of BH4, an enos cofactor important for maintaining enzymatic coupling. We examined the associations between haplotypes of the GCH1 gene, GCH1 expression and biopterin levels, and the effects on endothelial function and vascular superoxide production. Blood samples and segments of internal mammary arteries and saphenous veins were obtained from patients with CAD undergoing coronary artery bypass grafting (n 347). The GCH1 haplotypes were defined by 3 polymorphisms: rs87267g A, rs a T, and rs c G (X haplotype: A, T, G; O haplotype: any other combination). Vascular superoxide ( the enos inhibitor N G -nitro-l-arginine methyl ester [L-NAME]) was measured by lucigeninenhanced chemiluminescence, whereas the vasorelaxations of saphenous veins to acetylcholine were evaluated ex vivo. Haplotype frequencies were OO 7.6%, XO 27.4%, and XX 2.%. The X haplotype was associated with significantly lower vascular GCH1 messenger ribonucleic acid expression and substantial reductions in both plasma and vascular BH4 levels. In X haplotype carriers both vascular superoxide and L-NAME inhibitable superoxide were significantly increased, and were associated with reduced vasorelaxations to acetylcholine. GCH1 gene expression, modulated by a particular GCH1 haplotype, is a major determinant of BH4 bioavailability both in plasma and in the vascular wall in patients with CAD. Genetic variation in GCH1 underlies important differences in endogenous BH4 availability and is a determinant of enos coupling, vascular redox state, and endothelial function in human vascular disease. (J Am Coll Cardiol 28;52:158 65) 28 by the American College of Cardiology Foundation Maintenance of endothelial function is a critical aspect of vascular homeostasis. Loss of normal endothelial production of nitric oxide (NO) is an early and characteristic feature of From the *Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Neural Plasticity Research Group, Department of Anesthesia and Critical Care, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Pharmazentrum Frankfurt/ZAFES, Institute for Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany; Departments of Medicine and Pharmacology, Jagiellonian University, Cracow, Poland; and the Athens University Medical School, 1st Cardiology Department, Hippokration Hospital, Athens, Greece. This study was supported by the Marie Curie Intra-European Fellowship, within the 6th European Community Framework Programme (Dr. Antoniades). This work was also supported by the National Institute of Health Research Oxford Biomedical Research Centre Programme, and by grants from the British Heart Foundation (RG/2/6 to Dr. Channon, FS/3/15/1634 to Dr. Shirodaria). Drs. Costigan and Woolf were supported by the National Institutes of Health. Manuscript received November 2, 27; accepted December 12, 27. vascular disease states and plays a role in disease pathogenesis (1). Endothelial nitric oxide synthase (enos) is regu- See page 166 lated by the cofactor tetrahydrobiopterin (BH4) (2). Reduced BH4 availability in disease states seems to be an important aspect of impaired enos activity and increased vascular superoxide production (1,2). In humans with vascular disease states, acute administration of BH4 can improve endothelial function (3,4), and treatments such as folates or vitamin C, which improve endothelial function, may exert some of their effects by increasing BH4 availability (5 9). However, the extent to which alterations in endogenous BH4 availability, rather than pharmacologic effects of
2 JACC Vol. 52, No. 2, 28 July 8, 28: Antoniades et al. GCH1 Haplotypes and Vascular Biopterins 159 BH4, might play a direct role in modulating endothelial function in humans in vivo remains unclear. GTP cyclohydrolase I (GTPCH) is the rate-limiting enzyme in the biosynthesis of BH4 (1), and is a major determinant of BH4 levels, through transcriptional regulation of GCH1 expression. In some experimental models of vascular disease, reduced BH4 is associated with reduced GTPCH protein levels, suggesting reduced BH4 biosynthesis (11). However, BH4 oxidation by free radicals such as peroxynitrite (ONOO ), generating dihydrobiopterin (BH2) and biopterin (B), may cause loss of BH4 without changes in biopterin synthesis (5,7,12). The relative importance of synthesis versus oxidation of BH4 in atherosclerosis is complex because both local and systemic inflammation up-regulate GCH1 expression (13) but also increase ONOO production, potentially resulting in greater BH4 oxidation (14). In genetic mouse models, constitutive reduction in GCH1 expression causes BH4 deficiency, resulting in abnormal enos regulation (14 16). Conversely, transgenic overexpression of GTPCH in the vascular endothelium is sufficient to augment vascular BH4 levels (17), improve endothelial function in models of vascular disease (14), and rescue the vascular effects of genetic BH4 deficiency (16). Thus, in experimental models, genetic alteration of endogenous BH4 biosynthesis has provided useful insights into the role of BH4 in vascular disease pathogenesis. In contrast, it is unknown whether alterations in endogenous BH4 synthesis in humans are sufficient to alter systemic or vascular BH4 availability, or have any impact on vascular function. We have recently identified a novel haplotype of the GCH1 gene that is associated with significantly lower GTPCH activity in stimulated leukocytes (18,19). This haplotype is defined by 3 single nucleotide polymorphisms: rs87267g A in the putative promoter region, rs a T in intron 1 and rs c G in the 3= untranslated region of the GCH1 gene (18,19). In this study we examined the functional effects of this GCH1 haplotype on the levels of BH4 and total biopterins both in plasma and in vessels obtained from patients with coronary artery disease (CAD). Furthermore, we investigated how intrinsic genetic variation in vascular BH4 biosynthesis alters regulation of enos function in the human vasculature through effects on superoxide production and NO-mediated endothelial function. Methods Study subjects. We studied 347 patients with CAD undergoing elective coronary artery bypass grafting (CABG) at the John Radcliffe Hospital, Oxford, United Kingdom. Exclusion criteria were any inflammatory, infective, liver, or renal disease; malignancy; acute coronary event during the last 2 months; or clinically overt heart failure. Patients receiving nonsteroidal anti-inflammatory drugs, dietary supplements of folic acid, or antioxidant vitamins were also Abbreviations and Acronyms ACh acetylcholine BH4 tetrahydrobiopterin BH2 dihydrobiopterin B biopterin CABG coronary artery bypass grafting CAD coronary artery disease CRP C-reactive protein enos endothelial nitric oxide synthase GTPCH GTPcyclohydrolase I IMA internal mammary artery L-NAME N G -nitro-larginine methyl ester NO nitric oxide O 2 superoxide radical ONOO peroxynitrite Ox-LDL oxidized lowdensity lipoprotein RT-qPCR real-time quantitative polymerase chain reaction SNP sodium nitroprusside SV saphenous vein. excluded. Demographic characteristics of the patients are presented in Table 1. The study was approved by the local research ethics committee, and each patient gave written informed consent. Plasma and tissue samples. Blood samples were obtained immediately before surgery, after overnight fasting. Samples were centrifuged at 2,5 rpm for 1 min, and serum or plasma was stored at 8 o C until assayed. Samples of saphenous vein (SV) and internal mammary artery (IMA) were obtained at the time of CABG surgery, as we have previously described (5,2). Paired vessel segments were snap-frozen and stored at 8 o C for measurement of biopterin content, or were transferred to the laboratory for functional studies within 3 min, in ice cold Krebs-Henseleit buffer (5,2). Deoxyribonucleic acid (DNA) extraction and genotyping. Genomic DNA was extracted from 2 ml of whole blood using standard methods (QIAamp DNA blood Midi kit, Qiagen, Germantown, Maryland). In addition, DNA samples were available from 741 unrelated subjects of Caucasian ethnicity (mostly medical students) who had consented into genotyping and served as control subjects for allelic frequencies in the present study. The DNA samples were screened for that particular functional GCH1 haplotype identified as being associated with decreased GCH1 expression and BH4 production in a previous study (21). The complete haplotype consists of 15 DNA positions of the GCH1 gene. However, as described elsewhere (19), the diagnosis of the particular GCH1 haplotype of present interest is possible with 1% sensitivity and specificity by screening for just 3 GCH1 singlenucleotide polymorphisms that span the entire DNA range of the haplotype: c. 961G A (dbsnp rs87267g A) in the 5= untranslated region, c A T (dbsnp rs a T) in intron 1, and c.*4279 (dbsnp rs c G) in the 3= untranslated region. Thus, for diagnosis purposes the haplotype of interest reduces to rs87267a/rs t/rs g. The GCH1 haplotype of interest was identified by means of validated Pyrosequencing screening assays (Pyrosequencer PSQ95, Uppsala, Sweden) diagnosing the 3 selected sodium nitroprussides (SNPs) (19). Two different types of positive control samples were implemented into all Pyrosequencing screening
3 16 Antoniades et al. JACC Vol. 52, No. 2, 28 GCH1 Haplotypes and Vascular Biopterins July 8, 28: Demographic Characteristics of Patients Table 1 Demographic Characteristics of Patients Number of patients 347 Male/female 292/55 Age (yrs) Saphenous veins (n) 289 Internal mammary arteries (n) 166 Risk factors Hypertension (%) 72.7 Hypercholesterolemia (%) 71.6 Smokers (current/ex) (%) 8.6/69.8 Diabetes mellitus (%) 27.5 Family history for coronary artery disease (%) 63.3 Body mass index (kg/m 2 ) Triglycerides (mmol/l) Cholesterol (mmol/l) High-density lipoprotein (mmol/l) C-reactive protein (mg/l) Plasma biopterin levels Plasma tetrahydrobiopterin (nmol/l) 2.46 ( ) Plasma dihydrobiopterin (nmol/l) ( ) Plasma biopterin (nmol/l) 4.9 ( ) Plasma total biopterins (nmol/l) ( ) BH4/tBio ratio Medication (%) Statins 9. ACEI/ARB 66. Calcium-channel blockers 4.8 Beta-blocker 74.6 Aspirin 87.1 Values expressed as mean SEM or median (25th to 75th percentile) unless otherwise noted. ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; BH4 tetrahydrobiopterin; tbio total biopterins. analyses. One positive control set contained DNA samples from carriers of the haplotype independently diagnosed for all 15 GCH1 DNA positions by the 5=-exonuclease method (22). The second set of positive controls consisted of DNA samples homozygous or heterozygous for the frequent or rare alleles at the 3 SNP positions at the GCH1 DNA, diagnosed externally by means of conventional sequencing (AGOWA GmbH, Berlin, Germany) (18,19). Ribonucleic acid (RNA) isolation and real-time quantitative polymerase chain reaction (RT qpcr). Snapfrozen vascular rings (IMA and SV) were initially lysed in Trizol reagent (Tri-Reagent, Sigma, St. Louis, Missouri), followed by RNA purification from the aqueous phase using the RNeasy Micro kit (Qiagen, Stanford, California). Ribonucleic acid was converted into complementary DNA (Superscript II reverse transcriptase, Invitrogen, Carlsbad, California), then subjected to qpcr using the TaqMan system (Applied Biosystems, Foster City, California; Assay ID GCH Hs69198_m1, Assay ID GAPDH Hs _g1) and analyzed on an icycleriq (Biorad, Hercules, California). Relative expression was calculated using the 2 C T method. Determination of plasma and vascular biopterin levels. BH4, BH2, and biopterin levels in plasma or vessel tissue lysates were each determined separately from the same sample, by high-performance liquid chromatography followed by serial electrochemical and fluorescent detection, as previously described (23). Total biopterins were quantified by summing BH4, BH2, and B. Biopterin levels were expressed as pmol/g of tissue for vessels and nmol/l for plasma. Determination of vascular superoxide production. Vascular superoxide production was measured in paired segments of SV using lucigenin-enhanced chemiluminescence as previously described (5,24). Vessels were opened longitudinally to expose the endothelial surface and equilibrated for 2 min in oxygenated (95% O 2 /5% CO 2 ) Krebs-4-(2- hydroxyethyl)-1-piperazine-ethane-sulfonic acid buffer (ph 7.4) at 37 C. Lucigenin-enhanced chemiluminescence was measured using low-concentration lucigenin (5 mol/l) (25) because higher concentrations of lucigenin (up to 25 mol/l) favor redox cycling (24). As a measure of enos coupling we determined NOS-derived superoxide production, which was estimated as the difference in superoxide production after 2 min incubation with the NOS inhibitor N G -nitro-l-arginine methyl ester (L-NAME) (1 mol/l). Vasomotor studies. Endothelium-dependent and -independent dilatations were assessed in SV obtained at the time of CABG, using isometric tension studies (5,26). Four rings from each vessel were pre-contracted with phenylephrine (3 1 6 mol/l), then endothelium-dependent relaxations were quantified using acetylcholine (ACh, 1 9 to 1 5 mol/l). Finally, relaxations to the endothelium-independent NO donor SNP (1 1 to 1 6 mol/l) were evaluated in the presence of L-NAME (1 mol/l) as we have previously described (5,26). Determination of oxidized low-density lipoprotein (ox- LDL) and C-reactive protein (CRP) levels. Serum levels of ox-ldl were measured by enzyme-linked immunosorbent assay using commercially available kit (Mercodia, Sweden). Serum levels of CRP were measured by immunonephelometry using a high-sensitivity method (Dade Behring Marburg GmbH, Marburg, Germany). Statistical analysis. GCH1 haploblocks and linkage disequilibrium among the 3 SNPs with parameters D= and r 2 (27,28) were analyzed using the solid spine of LD algorithm implemented in Haploview (29). Allelic frequencies of the patient cohorts were compared with those observed in a random sample of 741 healthy unrelated control subjects of Caucasian ethnicity (mainly medical students of the University of Frankfurt am Main, Germany) by means of the Fisher exact test. On the basis of the observed allelic frequency, the expected number of homozygous and heterozygous carriers of the respective SNP was calculated using the Hardy-Weinberg equation as p 2 2pq q 2 1, where p and q are defined as the probabilities of occurrence for the dominant and mutated alleles, respectively (3). The correspondence between the observed numbers of homozygous and heterozygous individuals and the numbers expected on the basis of the Hardy-Weinberg equilibrium,
4 JACC Vol. 52, No. 2, 28 July 8, 28: Antoniades et al. GCH1 Haplotypes and Vascular Biopterins 161 indicating that the study sample corresponded to a random sample of subjects, was assessed using the chi-square goodness of fit test. Allelic frequencies of the cohort of 347 patients were compared with those observed in a random sample of 741 healthy unrelated control subjects of Caucasian ethnicity (mainly medical students of the University of Frankfurt am Main, Germany) by means of the Fisher exact test. Between these cohorts, the number of noncarriers, homozygous carriers, and heterozygous carriers of the particular GCH1 haplotype were compared using chi-square statistics. All variables were tested for normal distribution using the Kolmokorov-Smirnov test. Normally distributed variables are presented as mean SEM, whereas nonnormally distributed variables were log-transformed for analysis and are presented as median [25th to 75th percentiles] and range. Comparisons of baseline and demographic characteristics among the 3 genotypes were performed using one-way analysis of variance for multiple comparisons, whereas an unpaired t test was used to compare variables between 2 groups (for recessive models). Univariate analysis was performed by calculation of the Pearson coefficient. Multivariate analysis was used to examine the effect of the genotype on vascular/plasma biopterins, vascular superoxide, L-NAME induced change of vascular superoxide, or maximum relaxations to ACh as dependent variables. As independent variables we used GCH1 genotype, and those clinical characteristics (age, gender, diabetes mellitus, smoking, dyslipidemia, hypertension, body mass index, and medications) that showed an association with the dependent variable in univariate analysis at the level of 15%. A backward elimination procedure was applied in all models, having p.1 as the threshold to remove a variable from the model. All p values were 2-tailed, and a value of p.5 was considered statistically significant. All statistical analyses were performed using SPSS version 12. (SPSS Inc., Chicago, Illinois). Results We defined GCH1 haplotypes in 347 patients with CAD and 741 control subjects. In CAD patients, the 3 SNPs used to define the haplotypes were in linkage disequilibrium. Specifically, values of D= and r 2 were 95 and 77 for rs87267 and rs , 87 and 69 for rs and rs , and 86 and 5 for rs87267 and rs , respectively. The 3 SNPs were located within 1 single haploblock (29). The numbers of 245 noncarriers (OO) and 95 heterozygous (XO) and 7 homozygous (XX) carriers of the GCH1 X haplotype was in accordance with the Hardy- Weinberg law (chi-square goodness of fit test: p.81). Hardy-Weinberg equilibrium also applied to the control subjects (OO, n 543; XO, n 178; XX, n 2; chi-square goodness of fit test: p.51). The allelic frequencies of the GCH1 X haplotype of 15.7 and 14.7 in patients and healthy control subjects, respectively, did not differ between groups (Fisher exact test: p.56). Moreover, the numbers of noncarriers and heterozygous and homozygous carriers of the GCH1 X haplotype were similar in patients and control subjects (chi-square test: p.42). We first examined the effect of GCH1 haplotype on the levels of plasma biopterins. Patients with the X haplotype had significantly lower plasma levels of both BH4 and total biopterins than patients homozygous for the common O haplotype; median plasma BH4 levels in patients with XX genotype were reduced by approximately 8% compared with OO patients. Indeed, plasma BH4 and total biopterin levels were reduced in a striking allele-dependent manner from OO, XO, and XX genotypes (Fig. 1). Because vascular biopterin levels are likely more important for enos regulation, and could plausibly be differentially regulated from plasma biopterin levels, we next sought to examine the effect of GCH1 haplotype on vascular biopterins, in both SV and IMA. The presence of the X haplotype was associated with significantly lower levels of vascular BH4 and total biopterins in both SV and IMA (Fig. 1). These findings suggest a direct effect of this GCH1 haplotype on biopterin synthesis. A Plasma BH4 (nmol/l) C SV BH4 (pmol/g) E IMA BH4 (pmol/g) Figure P<.1 P<.1 P<.1 B Plasma tbio (nmol/l) D SV tbio (pmol/g) F IMA tbio (pmol/g) P<.1 P<.1 P<.5 OO XO XX OO XO XX Effect of GCH1 Haplotype on Plasma/Vascular BH4 The presence of the haplotype (XO or XX) was associated with significantly lower levels of plasma tetrahydrobiopterin (BH4) (A) and total biopterins (tbio) (B). A similar effect was also observed in saphenous veins (SV) (C and D) and internal mammary arteries (IMA) (E and F).
5 162 Antoniades et al. JACC Vol. 52, No. 2, 28 GCH1 Haplotypes and Vascular Biopterins July 8, 28: To investigate whether the effect of the GCH1 haplotype on biopterin levels was mediated by changes in GCH1 gene expression, we performed RT-PCR to quantify GCH1 messenger (m)rna in samples of SV and IMA from patients with different GCH1 genotypes. We observed that the XX genotype was associated with significantly reduced vascular GCH1 expression compared with the OO genotype (Fig. 2). Furthermore, vascular GCH1 mrna levels across all genotypes were significantly correlated with both plasma (r.394, p.1) and vascular (r.336, p.42) BH4 levels. We next sought to investigate how these genetically determined differences in biopterin levels might influence NOmediated endothelial function and vascular superoxide production. Because homozygosity for the X haplotype is relatively uncommon (2% of our population), we used a recessive model, comparing patients with or without X haplotype. In support of the recessive model, patients with at least 1 X haplotype (i.e., XO or XX genotypes) had significantly lower BH4 and total biopterins than OO patients, in both plasma (16.6 [5.2 to 28.3] and 41.2 [23.4 to 54.9] nmol/l vs [12.1 to 45.24] and 48.3 [32.6 to 76.4] nmol/l, p.5 for both) and SV (7.1 [2.2 to 9.3] and 32 [22 to 93] nmol/l vs. 11. [5.7 to 17.8] and 43 [24 to 76] nmol/g, p.5 for both). Vascular superoxide production was significantly increased in X haplotype carriers (Fig. 3). To explore the specific contribution of enos coupling, we quantified the difference in vascular superoxide production after NOS inhibition by L-NAME. Incubation of vessels with L-NAME inhibited superoxide production to a significantly greater extent in X haplotype carriers than in OO homozygotes (Fig. 3). Increased oxidative stress in X haplotype carriers was also supported by the observation of A Vascular O 2- (RLU/sec/mg) C BH4:tBio Ratio E ACh relaxation (%) Figure OO P<.1 P<.5 P<.5 XO+XX B LNAME Δ[O 2- ] (RLU/sec/mg) D SNP relaxation (%) Oxidized-LDL (IU/L) F OO P<.1 P<.5 P=NS XO+XX Effect of GCH1 Haplotype on Vascular Superoxide, Oxidative Stress, and Endothelial Function The presence of the X haplotype was associated with higher total superoxide (O 2 ) production (A) and greater L-NAME-inhibitable delta[o 2 ] (B) in human saphenous veins. The X haplotype was also associated with significantly lower plasma BH4:tBio ratio (C) and higher plasma levels of oxidized low-density lipoprotein (ox-ldl) (D). In addition, the X haplotype was also associated with lower maximum vasorelaxations in response to acetylcholine (ACh) (E) in saphenous veins, although it had no impact on the vasomotor responses to sodium nitroprusside (SNP) (F). Figure 2 Effect of GCH1 Haplotype on Vascular GTPCH mrna Levels The presence of the XX genotype was associated with significantly lower messenger ribonucleic acid (mrna) levels of GTPCH compared with OO genotype. Shown are the data derived from 23 saphenous veins (SVs) and 17 internal mammary arteries (IMAs). *p.5 versus OO. lower BH4:total biopterin ratio, and increased circulating levels of oxidized LDL (Fig. 3). To investigate how this GCH1 haplotype and the associated differences in biopterin levels modulate NOmediated endothelial function, we quantified the vasomotor responses of vessel segments to ACh in an organ bath system. Vasorelaxation responses to ACh were significantly reduced in X haplotype carriers than in OO homozygotes, whereas endothelium-independent vasomotor responses to the direct NO donor, SNP, were identical between genotypes (Fig. 3). Multivariate analysis. Because BH4 levels and endothelial function may potentially be altered by many factors, we used multivariate analysis to further investigate the relationships between the GCH1 haplotype and biopterin levels, taking into account other clinical and demographic factors. Presence of the X haplotype was an independent predictor of reduced BH4 levels in both plasma and vascular tissue (plasma: [SE] [4.722], p.14; SV: [SE]
6 JACC Vol. 52, No. 2, 28 July 8, 28: Antoniades et al. GCH1 Haplotypes and Vascular Biopterins [1.47], p.39). Furthermore, presence of the X haplotype was independently associated with increased vascular superoxide production (SV: [SE] [.573], p.4) and with reduced vasorelaxations to ACh (SV: [SE] 5.34 [2.355], p.26). Of the other additional demographic and clinical factors, diabetes mellitus was independently associated with increased vascular superoxide production ( [SE] 1.52 [.619], p.16) and with reduced ACh vasorelaxations ( [SE] [2.313], p.2), and hypercholesterolemia with reduced ACh vasorelaxations ( [SE] 7.73 [2.236], p.1). Female gender was independently associated with reduced ACh vasorelaxations ( [SE] [2.741], p.6) and with reduced BH4 levels ( [SE] 5.24 [2.25], p.22). Discussion In this study we have identified a striking effect of a novel haplotype of the GCH1 gene on both plasma and vascular BH4 levels in patients with CAD, mediated through altered GCH1 expression. In turn, we have shown that these genetically determined differences in BH4 availability are independent and strong predictors of key features of endothelial function, including aspects of enos coupling such as vascular superoxide production and NO-mediated vasorelaxation. Tetrahydrobiopterin is an essential cofactor for enos function in the vascular endothelium, with increasingly recognized roles in the pathogenesis of vascular disease states through effects on enos coupling (1) in both the vascular wall and in circulating endothelial progenitor cells (31). However, little is known about the pathophysiologic control of endothelial BH4 levels in humans. In disease states such as atherosclerosis (32), diabetes mellitus (17,31), hypertension (12), or insulin resistance (33,34), vascular BH4 deficiency seems to be mediated, at least in part, by the increased intracellular oxidation of BH4 to BH2 and B by reactive oxygen species (such as ONOO )(7,32). However, other studies suggest that changes in BH4 biosynthesis, through regulation of the rate-limiting enzyme GTPCH (35), may also be an important mechanism regulating vascular BH4 bioavailability (34,36). The GCH1 gene, encoding GTPCH, is expressed in several cell types, such as macrophages (37), endothelial cells (38), and others. However, it has been unclear to what extent altered GCH1 expression in the human vascular wall is related to differences in vascular BH4 levels, or to aspects of endothelial function in subjects with vascular disease. We have now used the genetic strategy of Mendelian randomization in humans to investigate the functional effects of intrinsic differences in vascular GCH1 expression. The importance of GCH1 expression and GTPCH enzymatic activity in regulating BH4 availability is well established. Loss-of-function mutations of GCH1 cause severe BH4 deficiency, resulting in diseases such as doparesponsive dystonia (OMIM 12823) and variant phenylketonuria (OMIM 23391), because of dysfunction of the BH4-dependent enzymes tyrosine hydroxylase and phenylalanine hydroxylase. Experimental mouse models with alterations in systemic or vascular-specific GCH1 expression (1,16) have shown that GTPCH is a key regulator of vascular BH4 levels in vivo. For example, the hph-1 mouse has an ENU mutant allele that maps to the GCH1 locus, but without mutations in the either the GCH1 coding sequence or minimal promoter (1). The hph-1 allele results in reduced GCH1 expression and reduced BH4 levels, an intermediate phenotype in heterozygote animals and functional defects in both neurotransmitter and NO synthesis (16). We have recently shown that a specific GCH1 haplotype (whose presence we define as X and absence as O) confers significant reduction in the induction of GCH1 expression and biopterin levels in leukocytes after a forskolin or lipopolysaccharide challenge (18,19). Furthermore, this GCH1 haplotype is associated with changes in pain perception and the severity of postoperative pain, likely because of differences in GCH1 expression after nerve injury (18,19). In addition, systemic inflammation seems to be a key regulator of biopterin synthesis in patients with CAD because plasma biopterins are correlated with plasma CRP (39). We have now shown that the presence of the X haplotype is associated with lower levels of both plasma BH4 and total biopterins (which is the sum of BH4, BH2, and B, reflecting the overall biosynthetic activity of GTPCH) in patients with multivessel CAD. These patients represent a model of moderate inflammatory stimulation (mean CRP 2.2 mg/l, with range from.12 to 15.5 mg/l), consistent with the effect of the haplotype on the regulation of GCH1 expression in white blood cells in response to lipopolysaccharide exposure. This effect was observed not only in the uncommon XX genotype (2% of our population), but also in the X haplotype carriers (XO genotype; 27.4% of the population), suggesting that the X haplotype may be an important and common factor in regulating circulating biopterin levels in patients with CAD. Importantly, we observed that the effect of the X haplotype on plasma BH4 was paralleled by an effect on vascular BH4, and on GCH1 mrna levels in vascular tissue. It seems most likely that the functional SNP or SNPs in the GCH1 X haplotype block will have effects on GCH1 expression, for example through effects on transcription, or on GCH1 mrna stability and translation. However, we have no evidence that any of the SNPs used to define the GCH1 X haplotype have any direct functional effects. Indeed, the SNPs chosen to screen the GCH1 gene were not selected on the basis of possible functional importance. Further recent evidence suggests that another SNP, located in the 3= UTR of the GCH1 gene, is also associated with reduced biopterin-dependent effects (4). Whether this SNP is part of the same or another haploblock as the X haplotype identified in our studies remains to be seen. Further studies will be required to ascertain which component SNP or SNPs confer the
7 164 Antoniades et al. JACC Vol. 52, No. 2, 28 GCH1 Haplotypes and Vascular Biopterins July 8, 28: functional effects on GCH1 expression and how such an effect might be mediated. Our observations suggest that GCH1 haplotype plays a potentially important role in regulating vascular BH4 bioavailability in CAD. More generally, our results highlight the central role of GTPCH, and GCH1 gene expression in particular, as key regulators of biopterin availability in humans, and in the functional responses of the vascular endothelium in vascular disease states. In the vascular endothelium, BH4 mediates coupling of oxygen reduction to heme-catalyzed L-arginine oxidation to form NO and L-citrulline (2). Therefore, BH4 deficiency is proposed to lead to enos uncoupling, resulting in decreased NO bioavailability and increased production of superoxide radicals from the uncoupled enzymatic form (41). A BH4 deficiency is associated with enos uncoupling in experimental models (17), resulting in increased superoxide production and decreased NO bioavailability in the vascular wall (41). Indirect evidence from previous clinical studies suggested that increased BH4 bioavailability is associated with improved endothelial function and enos coupling (5,6). However, the impact of endogenous BH4 levels on vascular function in patients with vascular disease has remained uncertain. The identification of a GCH1 haplotype with a major effect on endogenous BH4 levels in patients with CAD provided us with a novel means to test the functional effect on BH4 in the vascular wall. Indeed, we observed that the presence of the X haplotype was associated with both higher vascular superoxide and a greater L-NAME inhibitable fraction of superoxide, representing superoxide derived from uncoupled enos. This finding supports the hypothesis that vascular BH4 regulates enos coupling in vessels from patients with CAD. The impact of the X haplotype on vascular redox state was also reflected in the systemic levels of ox-ldl and the BH4/total biopterin ratio, both systemic biomarkers of the overall oxidative stress status. To further evaluate the impact of the X haplotype on enos function, we examined its effect on the vasomotor responses of the same vessels to acetylcholine, observing that the X haplotype was associated with reduced vasorelaxations to acetylcholine, implying that it has a direct impact on NO bioavailability and endothelial function in these vessels. Importantly, we observed that the effects of this haplotype on vascular BH4, superoxide production, enos coupling, and endothelial function were independent of the presence of other risk factors for atherosclerosis, suggesting that this haplotype may prove to be an independent risk factor for atherosclerosis. Study limitations. Some limitations of the present study need to be acknowledged. We were unable to evaluate the effect of GCH1 haplotypes in vessels from healthy individuals because these measurements require surgical material (segments of SV and IMA grafts used in CABG) that is not available from healthy individuals. We evaluated endothelial function in isolated SV segments, rather than arterial segments, because of the limited quantity of arterial tissue available from IMA grafts. However, we have used SV in the past as a reliable model system for the study of human vascular endothelium (5,6,2). Finally, our use of lucigeninenhanced chemiluminescence provides only a measure of overall vascular superoxide generation rather than identifying the specific cell types involved. Conclusions In conclusion, we have shown that a novel haplotype of the GCH1 gene is a major determinant of BH4 bioavailability in both plasma and vascular endothelium in patients with CAD. Our findings show that GCH1 expression is a key regulator of vascular biopterin levels, and in turn an important determinant of vascular oxidative stress and endothelial function. Genetic differences in BH4 availability could have potentially important effects on vascular disease pathogenesis, and provide a means to test the effects of BH4 on clinical outcomes and cardiovascular risk, a question that will need to be addressed in large case-control and prospective follow-up studies. Reprint requests and correspondence: Dr. Keith M. Channon, Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom. keith.channon@cardiov.ox.ac.uk. REFERENCES 1. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 23;91: 7A 11A. 2. Channon KM. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med 24;14: Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997;99: Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 2;86:E Antoniades C, Shirodaria C, Warrick N, et al. 5-methyl-tetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and enos coupling. Circulation 26;114: Shirodaria C, Antoniades C, Lee J, et al. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation 27;115: Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 23;278: Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2;86: Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97: Khoo JP, Nicoli T, Alp NJ, Fullerton J, Flint J, Channon KM. Congenic mapping and genotyping of the tetrahydrobiopterindeficient hph-1 mouse. Mol Genet Metab 24;82: Meininger CJ, Marinos RS, Hatakeyama K, et al. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J 2;349:353 6.
8 JACC Vol. 52, No. 2, 28 July 8, 28: Antoniades et al. GCH1 Haplotypes and Vascular Biopterins Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 23;111: Huang A, Zhang YY, Chen K, Hatakeyama K, Keaney JF Jr. Cytokine-stimulated GTP cyclohydrolase I expression in endothelial cells requires coordinated activation of nuclear factor-kappab and Stat1/Stat3. Circ Res 25;96: Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 24;24: Cosentino F, Barker JE, Brand MP, et al. Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterindeficient mice. Arterioscler Thromb Vasc Biol 21;21: Khoo JP, Zhao L, Alp NJ, et al. A pivotal role for tetrahydrobiopterin in pulmonary hypertension. Circulation 25;111: Alp NJ, Mussa S, Khoo J, et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 23;112: Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 26;12: Lotsch J, Belfer I, Kirchhof A, et al. Reliable screening for a pain-protective haplotype in the GTP cyclohydrolase 1 gene (GCH1) through the use of 3 or fewer single nucleotide polymorphisms. Clin Chem 27;53: Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 22;15: Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 26;12: Shi L, Norling LA, Lau AS, Krejci S, Laney AJ, Xu Y. Real time quantitative PCR as a method to evaluate simian virus 4 removal during pharmaceutical protein purification. Biologicals 1999;27: Heales S, Hyland K. Determination of quinonoid dihydrobiopterin by high-performance liquid chromatography and electrochemical detection. J Chromatogr 1989;494: Skatchkov MP, Sperling D, Hink U, et al. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun 1999;254: Guzik TJ, West NEJ, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2;86: Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 22;53: Lewontin RC. The interaction of selection and linkage. II Optimum models. Genetics 1964;5: Gaut BS, Long AD. The lowdown on linkage disequilibrium. Plant Cell 23;15: Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 25;21: Hardy GH. Mendelian proportions in a mixed population. Science 198;28: Thum T, Fraccarollo D, Schultheiss M, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 27;56: Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoe-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 21;13: Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2;87: Shinozaki K, Hirayama A, Nishio Y, et al. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol 21;38: Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med 199;172: Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 2;347: Werner ER, Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 199;265: Linscheid P, Schaffner A, Blau N, Schoedon G. Regulation of 6-pyruvoyltetrahydropterin synthase activity and messenger RNA abundance in human vascular endothelial cells. Circulation 1998;98: Antoniades C, Shirodaria C, Crabtree M, et al. Altered plasma vs. vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function and inflammation. Circulation 27;116: Zhang L, Rao F, Zhang K, et al. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest 27;117: Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998;95: Key Words: tetrahydrobiopterin y endothelial nitric oxide synthase y GTP-cyclohydrolase I y superoxide y haplotype y atherosclerosis.
Γενετική της αρτηριακής δομής και λειτουργίας
Γενετική της αρτηριακής δομής και λειτουργίας Χ. Αντωνιάδης Καρδιολόγος Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford 1 η Καρδιολογική Κλινική, Ιατρική Σχολή Πανεπιστημίου
More informationTetrahydrobiopterin (BH 4 ) is an essential cofactor for
ltered Plasma Versus Vascular iopterins in Human therosclerosis Reveal Relationships etween Endothelial Nitric Oxide Synthase Coupling, Endothelial Function, and Inflammation Charalambos ntoniades, MD,
More informationPhenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine
Phenylketonuria (PKU) the Biochemical Basis Biol 405 Molecular Medicine PKU a history In 1934 Følling identified a clinical condition - imbecillitas phenylpyruvica. Mental retardation associated with this
More informationLoss of normal endothelial function is an independent risk
Induction of Vascular GTP-Cyclohydrolase I and Endogenous Tetrahydrobiopterin Synthesis Protect Against Inflammation-Induced Endothelial Dysfunction in Human Atherosclerosis Charalambos Antoniades, MD,
More informationAssociation between interleukin-17a polymorphism and coronary artery disease susceptibility in the Chinese Han population
Association between interleukin-17a polymorphism and coronary artery disease susceptibility in the Chinese Han population G.B. Su, X.L. Guo, X.C. Liu, Q.T. Cui and C.Y. Zhou Department of Cardiothoracic
More informationPCTH 400. Endothelial dysfunction and cardiovascular diseases. Blood vessel LAST LECTURE. Endothelium. High blood pressure
PCTH 400 LAST LECTURE Endothelial dysfunction and cardiovascular diseases. Classic Vascular pharmacology -chronic -systemic Local Vascular pharmacology -acute -targeted High blood pressure Blood pressure
More informationNitric oxide (NO), produced by endothelial NO synthase
Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease Nicholas J. Alp, Keith M. Channon Abstract Nitric oxide (NO), produced by endothelial nitric oxide synthase (enos),
More informationLipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3701 CV Health Plus Genomics - Plasma, Serum & Buccal Swab Methodology: Chemiluminescent, Enzymatic, Immunoturbidimetric, NMR and PCR Lipid Markers Cholesterol LDL-
More informationNitroglycerin (GTN) has been used for more than a
Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction and Nitrate Tolerance A Human In Vivo Study Tommaso Gori, MD; Jason M. Burstein, MD; Sofia Ahmed, MD; Steve E.S. Miner, MD; Abdul
More informationDepartment of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom 2
Tetrahydrobiopterin-dependent preservation of nitric oxide mediated endothelial function in diabetes by targeted transgenic GTP cyclohydrolase I overexpression Nicholas J. Alp, 1 Shafi Mussa, 1 Jeffrey
More informationTargeting intracellular arginine / asymmetric dimethylarginine (ADMA).
Targeting intracellular arginine / asymmetric dimethylarginine (ADMA). From bench to practice: Novel anti-atherogenic strategies to improve endothelial function Rainer H. Böger, M.D. Institute of Clinical
More informationPhiladelphia College of Osteopathic Medicine Annual Progress Report: 2011 Formula Grant
Philadelphia College of Osteopathic Medicine Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Philadelphia College of Osteopathic Medicine
More informationPCTH 400. Drugs that improve endothelial function. Atherosclerosis LAST LECTURE
PCTH 400 LAST LECTURE Drugs that improve endothelial function. Pascal N. Bernatchez, Assistant Professor icapture Research Centre Dept. Anesthesiology, Pharmacology & Therapeutics University of British
More informationRegence. Medical Policy Manual. Date of Origin: May Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment
Regence Medical Policy Manual Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment Date of Origin: May 2013 Section: Genetic Testing Last Reviewed Date: June 2013
More informationMolecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer
Molecular mechanisms & clinical consequences of prothrombin mutations A.J. Hauer 07-12-2018 Prothrombin & the coagulation cascade Coagulation factor II, thrombin. Prothrombin is synthesized in the liver
More informationCardioGenomicPlus Profile
CardioGenomicPlus Profile Patient: SAMPLE PATIENT DOB: Sex: MRN: Apo E Chromosome 19 APOE APO E2: cys / cys APO E3: cys / arg APO E4: arg / arg The two SNPs lead to 3 possible variants for each chromosome,
More informationAssociation between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis
Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the
More informationCHAPTER 2. Detection of nitric oxide and reactive oxygen species
CHAPTER 31 Chapter Introduction Nitric oxide (NO) is one of the key players in the vasculature. It is involved in vessel dilation, inhibition of platelet and leukocyte adhesion, and inhibition of proliferation
More informationRelationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases
Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases Introduction Reactive oxygen species (ROS),such as superoxide and
More informationThe Role of Massage in Blood Circulation, Pain Relief, and the Recovery Process: Implications of Existing Research
The Role of Massage in Blood Circulation, Pain Relief, and the Recovery Process: Implications of Existing Research I. Basic Physiology of Circulation A. The Vascular Endothelium The endothelium is a complex
More informationTetrahydrobiopterin in Cardiovascular Health and Disease
ANTIOXIDANTS & REDOX SIGNALING Volume 20, Number 18, 2014 ª Mary Ann Liebert, Inc. DOI: 10.1089/ars.2013.5566 COMPREHENSIVE INVITED REVIEW Tetrahydrobiopterin in Cardiovascular Health and Disease Jennifer
More informationSupplementary Information Titles Journal: Nature Medicine
Supplementary Information Titles Journal: Nature Medicine Article Title: Corresponding Author: Supplementary Item & Number Supplementary Fig.1 Fig.2 Fig.3 Fig.4 Fig.5 Fig.6 Fig.7 Fig.8 Fig.9 Fig. Fig.11
More informationNitric oxide (NO) is generated from the conversion of
Brief Reviews Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis Seinosuke Kawashima, Mitsuhiro Yokoyama Abstract Atherosclerosis is associated with an impairment of endothelium-dependent
More informationH 2 S: Synthesis and functions
H 2 S: Synthesis and functions 1 Signaling gas molecules: O 2, NO and CO Then, H 2 S - Fourth singling gas molecule after O 2, NO and CO 2 Nothing Rotten About Hydrogen Sulfide s Medical Promise Science
More informationCt=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl)
a Control AAV mtm6sf-shrna8 Ct=4.3 Ct=8.4 Ct=8.8 Ct=8.9 Ct=.8 Ct=.5 Relative TM6SF mrna Level P=.5 X -5 b.5 Liver WAT Small intestine Relative TM6SF mrna Level..5 9.6% Control AAV mtm6sf-shrna mtm6sf-shrna6
More informationFor unclear reasons, only about 40% of patients with calcific aortic stenosis also have coronary
Αθηροσκλήρωση και ασβεστοποιός στένωση της αορτικής βαλβίδας. Οµοιότητες και διαφορές Ν. Μεζίλης Κλινική «Άγιος Λουκάς» Ασβεστοποιός στένωση της αορτικής βαλβίδας: Μία ακόµα µορφή αθηρωµάτωσης; Some observations
More informationAssociation between matrix metalloproteinase-9 rs polymorphism and development of coronary artery disease in a Chinese population
Association between matrix metalloproteinase-9 rs3918242 polymorphism and development of coronary artery disease in a Chinese population L.M. Qin 1, G.M. Qin 2, X.H. Shi 1, A.L. Wang 1 and H. Zuo 1 1 The
More informationPHENOTYPING FAMILIES OF A HYPERTENSIVE PATIENT
PHENOTYPING FAMILIES OF A HYPERTENSIVE PATIENT Christian Delles BHF Glasgow Cardiovascular Research Centre Advantages Cardiovascular of a Family-based ContinuumDesign Related subjects are more likely to
More informationEffects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats
Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats Y. Zhu 1, H.-S. Wang 1, X.-M. Li 1 and C. Qu 2 1 Department of Cardiac Surgery, General
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationSupplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
More informationNitric Oxide Synthase (nnos) Gene Transfer Modifies Venous Bypass Graft Remodeling
Nitric Oxide Synthase (nnos) Gene Transfer Modifies Venous Bypass Graft Remodeling Effects on Vascular Smooth Muscle Cell Differentiation and Superoxide Production Nick E.J. West, MRCP; HuSheng Qian, MD,
More informationPROTEIN METABOLISM: SPECIFIC WAYS OF AMINO ACIDS CATABOLISM AND SYNTHESIS
PROTEIN METABOLISM: SPECIFIC WAYS OF AMINO ACIDS CATABOLISM AND SYNTHESIS SPECIFIC WAYS OF AMINO ACID CATABOLISM After removing of amino group the carbon skeletons of amino acids are transformed into metabolic
More informationRecoupling the Cardiac Nitric Oxide Synthases: Tetrahydrobiopterin Synthesis and Recycling
Curr Heart Fail Rep (2012) 9:200 210 DOI 10.1007/s11897-012-0097-5 INVESTIGATIVE THERAPIES (J.-L. BALLIGAND, SECTION EDITOR) Recoupling the Cardiac Nitric Oxide Synthases: Tetrahydrobiopterin Synthesis
More informationCS2220 Introduction to Computational Biology
CS2220 Introduction to Computational Biology WEEK 8: GENOME-WIDE ASSOCIATION STUDIES (GWAS) 1 Dr. Mengling FENG Institute for Infocomm Research Massachusetts Institute of Technology mfeng@mit.edu PLANS
More informationFolic Acid Improves Endothelial Function in Coronary Artery Disease via Mechanisms Largely Independent of Homocysteine Lowering
Folic Acid Improves Endothelial Function in Coronary Artery Disease via Mechanisms Largely Independent of Homocysteine Lowering Sagar N. Doshi, BSc, MBChB, MRCP; Ian F.W. McDowell, MD, MRCP, FRCPath; Stuart
More informationLack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population
Lack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population J. Zhu 1 *, F. He 2 *, D.D. Zhang 2 *, J.Y. Yang 2, J. Cheng 1, R. Wu 1, B. Gong 2, X.Q. Liu
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationBackground and proposal for a pilot EQA scheme for pterins
Background and proposal for a pilot EQA scheme for pterins enad Blau Division of Inborn Metabolic Diseases University Children's Hospital Heidelberg Germany Tetrahydrobiopterin (BH 4 ) Brimstone butterfly
More informationGenetic testing in cardiovascular disease Atul K. Sachdev, MD
Genetic testing in cardiovascular disease Atul K. Sachdev, MD New Horizon Healthcare 1 Disclosures Speaker Quest/Cleveland HeartLab 9p21 The heart attack gene 9p21 is a region of the genome on the short
More informationInternational Graduate Research Programme in Cardiovascular Science
1 International Graduate Research Programme in Cardiovascular Science This work has been supported by the European Community s Sixth Framework Programme under grant agreement n LSHM-CT-2005-01883 EUGeneHeart.
More informationAnalysis of Neurotransmitters. Simon Heales
Analysis of Neurotransmitters Simon Heales HealeS@gosh.nhs.uk Tyrosine O 2 L-Dopa Dopamine HVA Tryptophan 5-HTP PLP Serotonin 5-HIAA Phenylalanine Tyrosine BH4 qbh2 BH2 CSF Sample Requirements Tube 1 Tube
More informationPUBLICATIONS. cells. J. Physiol. (London) 517P:91P (Manchester, England, UK).
277 PUBLICATIONS Abstracts Haddad JJ, Land SC (1999). Differential activation of oxygen-responsive transcription factors over fetal-to-neonatal alveolar oxygen tensions in rat fetal distal lung epithelial
More informationMoh Tarek + Faisal Massad. Tala Saleh ... Naif
19 Moh Tarek + Faisal Massad Tala Saleh... Naif Last lecture we ve talked about the main antioxidant system which are the enzymes found in our body, mainly: 1. Glutathione peroxidase 2. Super oxide dismutase(sod)
More informationDoctor of Philosophy
Regulation of Gene Expression of the 25-Hydroxyvitamin D la-hydroxylase (CYP27BI) Promoter: Study of A Transgenic Mouse Model Ivanka Hendrix School of Molecular and Biomedical Science The University of
More informationTreatment with Hydralazine and Nitrates Uri Elkayam, MD
Treatment with Hydralazine and Nitrates Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Hydralazine and Isosorbide Dinitrate
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationEndothelial Injury and Repair as a Working Paradigm
Endothelial Injury and Repair as a Working Paradigm A. Linke ESC Meeting 2010 UNIVERSITÄTLEIPZIG H ERZZEN TRUM Physiology of Endothelial Function: Regulation of Vascular Tone L-Arg. L-Arg. Agonists Shear
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationNAM JUNE PAIK: Rhapsody in Video
NAM JUNE PAIK: Rhapsody in Video 혈관연구회추계학회 2007.10.13 Renin-angiotensin-aldosterone System Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon University Gil Medical Center Incheon, Korea Cytokines oxldl Ang
More informationKey knowledge base & conceptual questions
Key knowledge base & conceptual questions Why is it said the pentose phosphate pathway is the major source of reducing power? What are the differences, in structure and in function, between NADH and NADPH?
More informationBy: Dr Mehrnoosh Shanaki
Resveratrol could partly improve the crosstalk between canonical β-catenin/wnt and FOXO pathways in coronary artery disease patients with metabolic syndrome: A case control study By: Dr Mehrnoosh Shanaki
More informationWhy Use Genetic Testing in Practice?
Pure Encapsulations is committed to producing the most complete line of research-based nutritional supplements. Available through health professionals, finished products are pure and hypoallergenic to
More informationEndothelium. A typical endothelial cell is about 30mm long, Accounts for 1% or less of the arterial weight
Endothelium Discovered in 1845 A typical endothelial cell is about 30mm long, 10mm wide, and 0.2 3 mm thick Accounts for 1% or less of the arterial weight As recently as the late 1960s it was thought of
More informationNovel Markers of Arterial Dysfunction
혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea Atherosclerosis: A progressive process PHASE I: Initiation
More informationNitric Oxide in the Penis: Scientific Discoveries and Clinical Applications
Nitric Oxide in the Penis: Scientific Discoveries and Clinical Applications Arthur L. (Bud) Burnett, M.D., M.B.A., F.A.C.S. Patrick C. Walsh Professor of Urology The James Buchanan Brady Urological Institute
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationReversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat
Diabetologia (1997) : 91 915 Springer-Verlag 1997 Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat G.M. Pieper, W. Siebeneich, G.
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationEndothelial dysfunction occurs in conjunction with coronary
Low-Density Lipoprotein Cholesterol Determines Oxidative Stress and Endothelial Dysfunction in Saphenous Veins From Patients With Coronary Artery Disease Sammy Al-Benna, Carlene A. Hamilton, John D. McClure,
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationJournal of the American College of Cardiology Vol. 38, No. 7, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 7, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01659-X Coronary
More informationInhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction
Inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction 4th Annual Pulmonary Hypertension Drug Discovery and Development Symposium July -, 7 Berlin,
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More information902 Biomed Environ Sci, 2014; 27(11):
902 Biomed Environ Sci, 2014; 27(11): 902-906 Letter to the Editor Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationWatermark. Interaction between Neuropathy and PAD
Interaction between Neuropathy and PAD Javier La Fontaine, DPM, MS Associate Professor Department of Plastic Surgery UT Southwestern Medical Center Dallas, Texas Objectives Understand vascular disease
More informationInhibition of Cytochrome P450 2C9 Improves Endothelium-Dependent, Nitric Oxide Mediated Vasodilatation in Patients With Coronary Artery Disease
Inhibition of Cytochrome P450 2C9 Improves Endothelium-Dependent, Nitric Oxide Mediated Vasodilatation in Patients With Coronary Artery Disease Stephan Fichtlscherer, MD; Stefanie Dimmeler, PhD; Susanne
More informationVascular action of the hypoglycaemic agent gliclazide in diabetic rabbits
Diabetologia (1998) 41: 9--15 Springer-Verlag 1998 Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits P. J. Pagano 1, M. C. Griswold 1, D. Ravel 2, R. A. Cohen 1 1 Vascular Biology
More informationUCLA Nutrition Noteworthy
UCLA Nutrition Noteworthy Title Vitamin C and the Risk of Coronary Heart Disease Permalink https://escholarship.org/uc/item/5xg9t04z Journal Nutrition Noteworthy, 4(1) ISSN 1556-1895 Author Chang, Angela
More informationTreatment with Hydralazine and Nitrates Uri Elkayam, MD
Treatment with Hydralazine and Nitrates Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Hydralazine and Isosorbide Dinitrate
More informationCho et al., 2009 Journal of Cardiology (2009), 54:
Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal
More informationReactive oxygen species: Importance for ischemia/reperfusion (injury)
Physiologisches Institut Reactive oxygen species: Importance for ischemia/reperfusion (injury) Prof. Dr. Rainer Schulz Reactive oxygen species (ROS) in ischemia/reperfusion injury (IRI) ROS GOOD: Endogenous
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationSupplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved
1 Supplemental Figure Legends Supplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved PCSK9 concentrations. 4 Plasma mature and furin-cleaved PCSK9s were measured by a sandwich
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationIn 1963, a naturally occurring coenzyme for phenylalanine
Tetrahydrobiopterin and Cardiovascular Disease An L. Moens, David A. Kass Abstract Tetrahydrobiopterin (BH 4 ) is an essential cofactor for the aromatic amino acid hydroxylases, which are essential in
More informationA novel role for vitamin D: modulation of expression and function of the local renin angiotensin system in mouse pancreatic islets
Diabetologia () 5:77 DOI.7/s5--- SHORT COMMUNICATION A novel role for vitamin D: modulation of expression and function of the local renin angiotensin system in mouse pancreatic islets Q. Cheng & Y. C.
More informationDuring the hyperinsulinemic-euglycemic clamp [1], a priming dose of human insulin (Novolin,
ESM Methods Hyperinsulinemic-euglycemic clamp procedure During the hyperinsulinemic-euglycemic clamp [1], a priming dose of human insulin (Novolin, Clayton, NC) was followed by a constant rate (60 mu m
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationHaplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis
Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationAssociation Study of RGS2 Gene Polymorphisms with Panic Disorder in Japanese
Kobe J. Med. Sci., Vol. 55, No. 5, pp. E116-E121, 2009 Association Study of RGS2 Gene Polymorphisms with Panic Disorder in Japanese KENTARO MOURI 1, AKITOYO HISHIMOTO 1*, MASAAKI FUKUTAKE 1, NAOKI NISHIGUCHI
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationCentral role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
More informationCardiovascular Division, Brigham and Women s Hospital, Harvard Medical School
Low Endothelial Shear Stress Upregulates Atherogenic and Inflammatory Genes Extremely Early in the Natural History of Coronary Artery Disease in Diabetic Hyperlipidemic Juvenile Swine Michail I. Papafaklis,
More informationCETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population
Wang et al. Lipids in Health and Disease 2013, 12:176 RESEARCH Open Access CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population Jun Wang 1, Li Jun Wang 1, Yong Zhong 1,2,
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationN itric oxide is synthesised from the amino acid L-
1319 CARDIOVASCULAR MEDICINE Effects of vitamin C on intracoronary dependent coronary vasodilatation in patients with stable angina D Tousoulis, C Xenakis, C Tentolouris, G Davies, C Antoniades, T Crake,
More informationSupplemental Figure I
Supplemental Figure I Kl ( mmol/l)-induced Force orta M (mn) 1 (mn) 1 Supplemental Figure I. Kl-induced contractions. and, Kl ( mmol/l)-induced contractions of the aorta () and those of mesenteric arteries
More informationCell Signaling (part 1)
15 Cell Signaling (part 1) Introduction Bacteria and unicellular eukaryotes respond to environmental signals and to signaling molecules secreted by other cells for mating and other communication. In multicellular
More informationAtherosclerosis 211 (2010) Contents lists available at ScienceDirect. Atherosclerosis
Atherosclerosis 211 (2010) 271 277 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Reduced LDL-cholesterol levels in patients with coronary
More informationHuman Genetics (Learning Objectives)
Human Genetics (Learning Objectives) Recognize Mendel s contribution to the field of genetics. Review what you know about a karyotype: autosomes and sex chromosomes. Understand and define the terms: characteristic,
More informationTETRAHYDROBIOPTERIN AND GTP CYCLOHYDROLASE I IN A RAT MODEL OF ENDOTOXIC SHOCK: RELATION TO NITRIC OXIDE SYNTHESIS
Experimental Physiology (1996), 81, 665-671 Printed in Great Britain TETRAHYDROBIOPTERIN AND GTP CYCLOHYDROLASE I IN A RAT MODEL OF ENDOTOXIC SHOCK: RELATION TO NITRIC OXIDE SYNTHESIS Y. HATTORI, N. NAKANISHI*,
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationMetabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI
Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI Narbeh Melikian*, Ajay M Shah*, Martyn R Thomas, Roy Sherwood, Mark T
More informationConduit Artery Constriction Mediated by Low Flow
Journal of the American College of Cardiology Vol. 51, No. 20, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.01.049
More information